|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2023-01-06
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06DX05
|
|
gptkbp:brand
|
gptkb:Leqembi
|
|
gptkbp:CASNumber
|
gptkb:2417893-86-2
|
|
gptkbp:chemicalClass
|
humanized IgG1 monoclonal antibody
|
|
gptkbp:clinicalTrialPhase
|
gptkb:CLARITY-AD
Phase 3
|
|
gptkbp:countryOfOperation
|
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Biogen
gptkb:Eisai
|
|
gptkbp:halfLife
|
6-7 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lecanemab
|
|
gptkbp:indication
|
mild cognitive impairment due to Alzheimer's disease
mild Alzheimer's dementia
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
amyloid beta protofibrils
|
|
gptkbp:mechanismOfAction
|
targets amyloid beta
|
|
gptkbp:prescriptionRequired
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s000lbl.pdf
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:ARIA-E
gptkb:ARIA-H
infusion-related reactions
|
|
gptkbp:UNII
|
6X8R1Y2K1F
|
|
gptkbp:usedFor
|
gptkb:Alzheimer's_disease
|
|
gptkbp:bfsParent
|
gptkb:CLARITY
|
|
gptkbp:bfsLayer
|
6
|